Molecular Partners AG (MOLN)Healthcare | Biotechnology | Schlieren, Switzerland | NasdaqGS
4.21 USD
+0.01
(0.119%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.06 -0.14 (-0.145%) ⇩ (April 17, 2026, 4:10 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:02 a.m. EDT
MOLN presents a high-risk, speculative profile for a biotech firm with negative earnings and cash flow, trading well below its analyst price targets due to recent price weakness; the lack of dividends combined with poor fundamentals makes it unsuitable for income or conservative capital preservation, though upside potential exists if pipeline catalysts (Radio-DARPins, DLL3 data) drive momentum. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.121536 |
| AutoETS | 0.121649 |
| MSTL | 0.123276 |
| AutoTheta | 0.124469 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.284 |
| Excess Kurtosis | -1.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.536 |
| Market Cap | 157,316,064 |
| Forward P/E | -16.97 |
| Beta | 0.74 |
| Website | https://www.molecularpartners.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.11538458 |
| Address1 | Wagistrasse 14 |
| All Time High | 32.04 |
| All Time Low | 3.32 |
| Ask | 0.0 |
| Ask Size | 0 |
| Average Daily Volume10 Day | 3,380 |
| Average Daily Volume3 Month | 4,064 |
| Average Volume | 4,064 |
| Average Volume10Days | 3,380 |
| Beta | 0.74 |
| Bid | 4.71 |
| Bid Size | 1 |
| Book Value | 2.7489972 |
| City | Schlieren |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.205 |
| Current Ratio | 8.785 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.205 |
| Day Low | 4.18 |
| Debt To Equity | 4.536 |
| Earnings Call Timestamp End | 1,741,345,140 |
| Earnings Call Timestamp Start | 1,741,345,140 |
| Earnings Timestamp | 1,773,345,600 |
| Earnings Timestamp End | 1,773,345,600 |
| Earnings Timestamp Start | 1,773,345,600 |
| Ebitda | -54,538,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.245 |
| Enterprise Value | 67,902,064 |
| Eps Current Year | -1.11731 |
| Eps Forward | -0.24776448 |
| Eps Trailing Twelve Months | -2.11 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 41 44 755 77 07 |
| Fifty Day Average | 4.54156 |
| Fifty Day Average Change | -0.33656025 |
| Fifty Day Average Change Percent | -0.074106745 |
| Fifty Two Week Change Percent | 11.538458 |
| Fifty Two Week High | 5.36 |
| Fifty Two Week High Change | -1.1550002 |
| Fifty Two Week High Change Percent | -0.21548511 |
| Fifty Two Week Low | 3.36 |
| Fifty Two Week Low Change | 0.845 |
| Fifty Two Week Low Change Percent | 0.25148812 |
| Fifty Two Week Range | 3.36 - 5.36 |
| Financial Currency | CHF |
| First Trade Date Milliseconds | 1,623,850,200,000 |
| Float Shares | 17,501,927 |
| Forward Eps | -0.24776448 |
| Forward P E | -16.971762 |
| Free Cashflow | -27,532,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 134 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -39,138,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.09595 |
| Implied Shares Outstanding | 37,411,668 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-16 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. |
| Long Name | Molecular Partners AG |
| Market | us_market |
| Market Cap | 157,316,064 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_32677064 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -61,651,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 156,174,278 |
| Number Of Analyst Opinions | 5 |
| Open | 4.18 |
| Operating Cashflow | -51,257,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 41 44 755 77 00 |
| Post Market Change | -0.14499998 |
| Post Market Change Percent | -3.4482756 |
| Post Market Price | 4.06 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 4.2 |
| Price Eps Current Year | -3.763503 |
| Price Hint | 4 |
| Price To Book | 1.5296487 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.557 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0050001144 |
| Regular Market Change Percent | 0.11905035 |
| Regular Market Day High | 4.205 |
| Regular Market Day Low | 4.18 |
| Regular Market Day Range | 4.18 - 4.205 |
| Regular Market Open | 4.18 |
| Regular Market Previous Close | 4.2 |
| Regular Market Price | 4.205 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,748 |
| Return On Assets | -0.26587 |
| Return On Equity | -0.55549 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 37,411,668 |
| Shares Percent Shares Out | 0.0004 |
| Shares Short | 16,194 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 17,248 |
| Short Name | Molecular Partners AG |
| Short Percent Of Float | 0.0008 |
| Short Ratio | 4.43 |
| Source Interval | 15 |
| Symbol | MOLN |
| Target High Price | 17.164257 |
| Target Low Price | 3.7856872 |
| Target Mean Price | 11.2464485 |
| Target Median Price | 12.114967 |
| Total Cash | 93,058,000 |
| Total Cash Per Share | 2.487 |
| Total Debt | 3,644,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.08203 |
| Two Hundred Day Average Change | 0.122970104 |
| Two Hundred Day Average Change Percent | 0.030124744 |
| Type Disp | Equity |
| Volume | 2,748 |
| Website | https://www.molecularpartners.com |
| Zip | 8,952 |